GLORIA PHARMA.(SZ:002437)2023-07-03 12:14Group 1: Company Performance and Financial Impact - The company has confirmed an investment loss of 35.74 million yuan from January to May 2023, with an estimated total impact on net profit for the year ranging from -8,000 to -9,000 million yuan [1] - The domestic biopharmaceutical industry is facing intensified competition, with several PD-1/PD-L1 related products approved for market, diminishing the competitive edge of the company's product [1] - The company plans to divest its entire stake in its subsidiary, Yuheng Biotech, due to significant losses affecting overall performance [1] Group 2: Research and Development Projects - Current research projects focus on orthopedic, cardiovascular, and vitamin/mineral fields, utilizing self-research, CRO partnerships, and collaborative development [2] - The company maintains a strong market position with its injectable compound vitamins, holding over 80% market share, and potassium chloride sustained-release tablets, which have increased market share to over 30% [2] Group 3: Production Capacity and Utilization - As of the end of 2022, the company operates 50 production lines with an annual capacity of 680 million injectable units and 2.65 billion oral solid units [3] - Utilization rates vary significantly across production lines, with potassium chloride sustained-release tablets exceeding 90% utilization, while some lines remain underutilized [3] Group 4: Market Strategy and Sales - The company aims to stabilize its existing business and explore first-generic drugs and new differentiated products in the short term, avoiding further investments in the biopharmaceutical sector for now [1] - The impact of centralized procurement policies on the company's main products is positive, particularly for potassium chloride sustained-release tablets, with no significant changes in overall revenue expected this year [3]